Granted Patent B2

US 9,079,960 · App. 13/594,619 · Granted Jul 14, 2015

Inventors: Seung Yup Chu (Cypress, CA); John R. Desjarlais (Pasadena, CA); Sher Bahadur Karki (Pomona, CA); Gregory Alan Lazar (Arcadia, CA); Gregory L. Moore (Monrovia, CA); Igor Vostiar (Monrovia, CA)

Assignee: Xencor, Inc.

C07K16/283C07K16/00C07K16/2803C07K16/2851C07K16/2878C07K2317/24C07K2317/52C07K2317/524C07K2317/53C07K2317/71C07K2317/72C07K2317/73C07K2317/732C07K2317/734C07K2317/77

Abstract

Claims (19)

1. An anti-CD19 immunoglobulin comprising:

a light chain; and

a heavy chain comprising an amino acid sequence of SEQ ID NO: 2 and amino acid substitution(s) in the Fc region selected from L234W, L235I, L235Y, L235R, L235D, G236D, G236N, S267D, S267E, L328F, and L328Y as compared to SEQ ID NO: 4, wherein the numbering is according to the EU index, as in Kabat.

2. The immunoglobulin of claim 1 , wherein the immunoglobulin comprises:

a light chain comprising an amino acid sequence of SEQ ID NO: 7.

3. The immunoglobulin of claim 1 , wherein the amino acid substitution(s) in the Fc region are selected from L234W, L235I, L235Y, L235R, G236D, S267D, S267E, and L328F.

4. The immunoglobulin according to claim 1 , wherein the amino acid substitution in the Fc region is S267E.

5. The immunoglobulin according to claim 1 , wherein the amino acid substitution in the Fc region is L328F.

6. The immunoglobulin according to claim 1 , wherein the amino acid substitution in the Fc region is S267E/L328F.

7. A pharmaceutical composition comprising the immunoglobulin according to claim 1 , and a pharmaceutically acceptable carrier.

8. The immunoglobulin of claim 2 , wherein the amino acid substitution(s) in the Fc region are selected from L234W, L235I, L235Y, L235R, G236D, S267D, S267E, and L328F.

9. The immunoglobulin according to claim 2 , wherein the amino acid substitution in the Fc region is S267E.

10. The immunoglobulin according to claim 2 , wherein the amino acid substitution in the Fc region is L328F.

11. The immunoglobulin according to claim 2 , wherein the amino acid substitution in the Fc region is S267E/L328F.

12. A pharmaceutical composition comprising the immunoglobulin according to claim 2 , and a pharmaceutically acceptable carrier.

13. The immunoglobulin of claim 1 , wherein the amino acid substitution(s) in the Fc region are selected from L235D/S267E, L235Y/S267E, L235D/S267D, L235I/S267E, L235I/S267D, L235Y/S267D, G236D/S267E, G236D/S267D, S267E/L328F, S267D/L328F, H268D/S267E, H268D/S267D, H268E/S267E, H268E/S267D, and G236N/S267E/L328F.

14. The immunoglobulin of claim 3 , wherein the amino acid substitution(s) in the Fc region are selected from L235D/S267E, L235Y/S267E, L235Y/S267D, G236D/S267E, S267E/L328F, H268D/S267E, H268E/S267E, H268E/S267D, and G236D/S267E/L328F.

15. The immunoglobulin of claim 8 , wherein the amino acid substitution(s) in the Fc region are selected from L235D/S267E, L235Y/S267E, L235Y/S267D, G236D/S267E, S267E/L328F, H268D/S267E, H268E/S267E, H268E/S267D, and G236D/S267E/L328F.

16. The immunoglobulin of claim 1 , wherein the amino acid substitution in the Fc region is S 267 D.

Assignments (1)

Continuity (14)